Table 1 Baseline characteristics of the study population.
Characteristics | Bezafibrate (n = 1506) | Placebo (n = 1505) | p value |
|---|---|---|---|
Age (years) | 60.0 ± 6.8 | 60.0 ± 6.7 | 0.9 |
Body mass index (kg/m2) | 26.7 ± 3.3 | 26.7 ± 3.3 | 0.7 |
Men (%) | 1374(91) | 1382 (92) | 0.6 |
Past myocardial infarction (%) | 1184 (79) | 1163 (77) | 0.3 |
Angina (%) | 848 (56) | 876 (58) | 0.3 |
NYHA Class ≥2 (%) | 45 (27) | 47 (26) | 0.9 |
Hypertension (%) | 462 (31) | 507 (34) | 0.1 |
Current smokers | 177 (12) | 184 (12) | 0.7 |
Systolic blood pressure (mmHg) | 134 ± 18 | 133 ± 18 | 0.3 |
Diastolic blood pressure (mmHg) | 81.1 ± 9.0 | 80.8 ± 9.1 | 0.4 |
Heart rate (beats/min) | 70.1 ± 9.3 | 70.0 ± 9.3 | 0.8 |
Total cholesterol (mg/dl) | 211 ± 17 | 213 ± 18 | 0.2 |
HDL-cholesterol (mg/dl) | 34.5 ± 5.5 | 34.6 ± 5.5 | 0.7 |
LDL-cholesterol (mg/dl) | 148 ± 16 | 149 ± 16 | 0.2 |
Triglycerides (mg/dl) | 145 ± 51 | 145 ± 51 | 0.9 |
Fibrinogen (mg/dl) | 350 ± 72 | 351 ± 74 | 0.7 |